Skip to main content
OpenTrials
Completed

NCT Number: NCT04157595

Mackenzie's Mission: The Australian Reproductive Carrier Screening Project

This study will investigate reproductive genetic carrier screening (RGCS) in 10,000 couples across Australia. Carrier screening for approximately 1300 genes associated with severe, childhood-onset, X-linked and autosomal recessive conditions will be performed on each member of the couple. A combined result will be issued indicating whether the couple has a 'low' or 'increased' risk of having a child with a genetic condition. It is anticipated that 1-2% of couples will be at an increased risk of having an affected child.

The study will evaluate all aspects of the RGCS program to assess the feasibility and acceptability of a publicly-funded population-wide RGCS program, including:

* education of recruiting healthcare providers * education of participating couples * implementation and uptake of RGCS * frequency of increased-risk couples and their reproductive decisions * psychosocial impacts * ethical issues * health economic implications * health implementation research

Completed

Looking for future studies?

Notify Me

Key information

Conditions

X-linked Genetic Diseases Autosomal Recessive Disorder Congenital, Hereditary, and Neonatal Diseases and Abnormalities Disease Attributes Genetic Diseases, Inborn Genetic Diseases, X-Linked Pathologic Processes Pathological Conditions, Signs and Symptoms Rare Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Forster Community Health Service, Forster, New South Wales, Australia

Loading trial locations.

About this study

PROTOCOL SYNOPSIS

Couples will be invited to take part in the study by their healthcare provider (HCP). The couple will enrol via an online portal, complete an education module, provide consent and complete a questionnaire. Those who consent to carrier screening will be sent mouth swab kits with samples returned by mail.The carrier screening performed will be done via accredited testing laboratories in partnership with clinical genetics services. Genetic counselling will be available to study participants throughout the process. Couples at increased risk will be offered a genetic counselling consultation and offered support to access reproductive options (i.e. prenatal diagnosis, preimplantation genetic diagnosis (PGD) which will be funded by the study for one cycle of IVF with PGD). All participants will be asked to complete an initial survey at study enrolment and invited to complete optional surveys at the time of screening, after return of screening results, and approximately 13 to 19 months after results. Subsets of participants will also be invited to take part in interviews.

GENE LIST FOR CARRIER SCREENING

The approximately 1300 genes tested in the Mackenzie's Mission carrier screening panel meet the following criteria:

  • The associated condition is one where an 'average' couple would take steps to prevent the birth of a child with that condition.
  • This includes conditions with significant negative impact on quality of life for the child, the condition being lethal in childhood, and a significant impact on the family.
  • AND/OR: There is a potential benefit for knowing about the condition to inform management in the neonatal period. This criterion was particularly important if the condition was either not included on a newborn screening panel, and/or intervention would be required prior to results from newborn screening being known.
  • AND there is strong evidence for mutations in the gene being causative of the condition in question, with enough variants reported to allow confidence in informing couples of their chance of having a child with the condition in question.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

In order to take part in the study, couples need to have visited a recruiting HCP who will assess them for eligibility based on the criteria below:

Inclusion criteria

  • Planning to become pregnant or in early pregnancy (less than 10 weeks gestation at enrolment and less than 11 weeks gestation at sample receipt by the laboratory)
  • Both members of the couple available to participate in the study and available to provide a sample for testing at the same time.
  • If the couples are using an egg/sperm donor/s, the donor/s need to be available to provide a DNA sample for testing and consent to having carrier screening.

NB: If both members of the couple are known carriers of the same autosomal recessive condition, or the female is a known carrier of an X-linked recessive condition, they will still be eligible to have RGCS through the study, but will only be considered an 'increased-risk' couple for the purposes of this study if they are identified through the study testing to be carriers of pathogenic variants in a different gene.

Exclusion criteria

Participating couples meeting any of the following requirements will be excluded from this study:

  • Pregnant and greater than 10 weeks gestation at enrolment.
  • Only one member of the couple agrees to participate in the study.
  • One or both members of the couple are less than 18 years old.
  • Both members of the couple are not available to be tested at the same time.
  • The couple are using an egg/sperm donor/s and the donor/s are not available for testing or the couple are using an anonymous donor.
  • One member of the couple has already been screened as part of the study.

Treatment and study plan

Reproductive Genetic Carrier Screening

Other

Carrier screening for approximately 1300 genes associated with severe autosomal recessive and X-linked recessive conditions affecting children will be performed on each member of the couple. A combined result will be issued indicating whether the couple has a 'low' or 'increased' risk of having a child with a genetic condition

Primary outcomes

  1. Screening Uptake (Quantitative)

    Time frame: At offer of screening

    Practitioners offering screening will be asked to record the number of couples offered screening which will allow calculation of screening uptake.

  2. Frequency of Increased-Risk Couples

    Time frame: At reporting of results (~Weeks 5-6 since enrolment)

    Analysis of carrier frequencies of the genes tested and the frequency of identification of increased-risk couples

  3. Reproductive Choices made by Increased-Risk Couples

    Time frame: Reproductive choices made by couples will be tracked from the date an increased-risk result is received until study closure on 31 December 2022. A subset of couples will be interviewed ~19 months after receiving an increased-risk result.

    For pregnant couples, the investigators will ascertain how many have prenatal diagnosis (PND), and of those who have PND and an affected fetus is identified, how many terminate the pregnancy. For those who are not pregnant at the time of screening, the investigators will ascertain choices for future pregnancies that occur during the timeframe of the study, including how many choose preimplantation genetic diagnosis (PGD), how many choose a naturally conceived pregnancy with PND and how many choose a naturally conceived pregnancy without any testing.

  4. Cohort Characteristics of those who decline and those who accept RGCS

    Time frame: Couples who decline screening;at offer or at enrolment (Day 0); optional. Couples who accept screening; at enrolment (Day 0); compulsory.

    Short survey capturing personal information: age, country of birth, language spoken at home, ethnicity, religion and religiosity, education level, employment status, household income, marital status, pregnancy history and family/genetic history information.

  5. Predictors of Uptake - Decliners

    Time frame: Couples who decline screening; at offer or enrolment (Day 0); optional

    Survey asking main reason(s) for declining to participate informed by the Health Belief Model (HBM). The HBM is used to predict and explain uptake of a health behaviour. It includes four components: perceived benefits, perceived susceptibility, perceived severity and perceived barriers (Janz and Becker 1984). A subset of declining couples will be invited for interview to explore the decision-making process and their reasons for declining testing.

  6. Predictors of Uptake - Decliners

    Time frame: At decision not to provide samples for screening, anticipated to be within ten days of enrolment (Days 2-10); optional

    Survey asking main reason(s) for declining to participate informed by the Health Belief Model (HBM). The HBM is used to predict and explain uptake of a health behaviour. It includes four components: perceived benefits, perceived susceptibility, perceived severity and perceived barriers (Janz and Becker 1984). A subset of declining couples will be invited for interview to explore the decision-making process and their reasons for declining testing.

  7. Predictors of Uptake - Acceptors

    Time frame: Couples who accept screening; at offer or enrolment (Day 0); compulsory.

    Survey asking main reason(s) for choosing to participate informed by the Health Belief Model (HBM). The HBM is used to predict and explain uptake of a health behaviour. It includes four components: perceived benefits, perceived susceptibility, perceived severity and perceived barriers (Janz and Becker 1984)

  8. Predictors of Uptake - Acceptors

    Time frame: At provision of samples for screening, anticipated to be within ten days of enrolment (Days 2-10); optional

    Survey asking main reason(s) for choosing to participate informed by the Health Belief Model (HBM). The HBM is used to predict and explain uptake of a health behaviour. It includes four components: perceived benefits, perceived susceptibility, perceived severity and perceived barriers (Janz and Becker 1984)

Secondary outcomes

  1. Participant Experience - Attitudes/Perceptions

    Time frame: Couples who decline screening;at offer or at enrolment (Day 0); optional. Couples who accept screening; at enrolment (Day 0); compulsory.

    Survey assessing attitudes towards carrier screening in the general population, and the attitudes of the couple towards carrier screening for themselves.

  2. Participant Experience - State-Anxiety - pre-screening

    Time frame: Couples who decline screening; at enrolment (Day 0); optional. Couples who accept screening; at enrolment (Day 0); compulsory.

    Six-item short-form of the state-anxiety scale of the Spielberger State-Trait Anxiety Inventory (STAI) (Marteau and Bekker 1992). This scale measures how the respondent feels "right now, at this moment". Scores range from 20 to 80. A high score indicates the presence of high levels of anxiety.

  3. Participant Experience - State-Anxiety - pre-screening II

    Time frame: At provision of samples for screening, anticipated to be within ten days of enrolment (Days 2-10); optional

    Six-item short-form of the state-anxiety scale of the Spielberger State-Trait Anxiety Inventory (STAI) (Marteau and Bekker 1992). This scale measures how the respondent feels "right now, at this moment". Scores range from 20 to 80. A high score indicates the presence of high levels of anxiety.

  4. Participant Experience - State-Anxiety - post-result

    Time frame: Low-risk and increased-risk couples; post-result (~Weeks 17-18 since enrolment); optional

    Six-item short-form of the state-anxiety scale of the Spielberger State-Trait Anxiety Inventory (STAI) (Marteau and Bekker 1992). This scale measures how the respondent feels "right now, at this moment". Scores range from 20 to 80. A high score indicates the presence of high levels of anxiety.

  5. Participant Experience - State-Anxiety - long-term follow-up

    Time frame: Low-risk couples; long-term follow-up (~13 months since enrolment); optional. Increased-risk couples; long-term follow-up (~19 months since enrolment); optional

    Six-item short-form of the state-anxiety scale of the Spielberger State-Trait Anxiety Inventory (STAI) (Marteau and Bekker 1992). This scale measures how the respondent feels "right now, at this moment". Scores range from 20 to 80. A high score indicates the presence of high levels of anxiety.

  6. Participant Experience - Trait-Anxiety - pre-screening

    Time frame: Couples who decline screening; at enrolment (Day 0); optional. Couples who accept screening; at enrolment (Day 0); compulsory.

    20-item trait-anxiety scale (Form Y2) of the Spielberger State-Trait Anxiety Inventory (STAI). This scale measures how the respondent "generally" feels. Scores range from 20 to 80. A high score indicates the presence of high levels of anxiety.

  7. Participant Experience - Trait-Anxiety - pre-screening II

    Time frame: At provision of samples for screening, anticipated to be within ten days of enrolment (Days 2-10); optional

    20-item trait-anxiety scale (Form Y2) of the Spielberger State-Trait Anxiety Inventory (STAI). This scale measures how the respondent "generally" feels. Scores range from 20 to 80. A high score indicates the presence of high levels of anxiety.

  8. Participant Experience - Trait-Anxiety - post-result

    Time frame: Low-risk and increased-risk couples; post-result (~Weeks 17-18 since enrolment); optional

    20-item trait-anxiety scale (Form Y2) of the Spielberger State-Trait Anxiety Inventory (STAI). This scale measures how the respondent "generally" feels. Scores range from 20 to 80. A high score indicates the presence of high levels of anxiety.

  9. Participant Experience - Trait-Anxiety - long-term follow-up

    Time frame: Low-risk couples; long-term follow-up (~13 months since enrolment); optional. Increased-risk couples; long-term follow-up (~19 months since enrolment); optional

    20-item trait-anxiety scale (Form Y2) of the Spielberger State-Trait Anxiety Inventory (STAI). This scale measures how the respondent "generally" feels. Scores range from 20 to 80. A high score indicates the presence of high levels of anxiety.

  10. Health Economic Impact - Assessment of Quality of Life - pre-screening

    Time frame: Couples who decline testing, at enrolment (Day 0); optional. Couples who accept testing, at enrolment (Day 0); compulsory

    12-item Assessment of Quality of Life-4D (AQoL-4D) questionnaire (Hawthorne, Richardson and Osbourne 1999; Richardson and Hawthorne 1998). This questionnaire measures health-related quality of life in four dimensions: Independent Living, Relationships, Mental Health and Senses. Total scores range from a minimum of 12 to a maximum of 48. Higher scores indicate a lower health-related quality of life.

  11. Health Economic Impact - Assessment of Quality of Life - post-result

    Time frame: Low-risk and increased-risk couples; post-result (~Weeks 17-18 since enrolment); optional

    12-item Assessment of Quality of Life-4D (AQoL-4D) questionnaire (Hawthorne, Richardson and Osbourne 1999; Richardson and Hawthorne 1998). This questionnaire measures health-related quality of life in four dimensions: Independent Living, Relationships, Mental Health and Senses. Total scores range from a minimum of 12 to a maximum of 48. Higher scores indicate a lower health-related quality of life.

  12. Health Economic Impact - Assessment of Quality of Life - long-term follow-up

    Time frame: Low-risk couples; long-term follow-up (~13 months since enrolment); optional. Increased-risk couples; long-term follow-up (~19 months since enrolment); optional

    12-item Assessment of Quality of Life-4D (AQoL-4D) questionnaire (Hawthorne, Richardson and Osbourne 1999; Richardson and Hawthorne 1998). This questionnaire measures health-related quality of life in four dimensions: Independent Living, Relationships, Mental Health and Senses. Total scores range from a minimum of 12 to a maximum of 48. Higher scores indicate a lower health-related quality of life.

  13. Health Economic Impact - Participants' willingness to pay

    Time frame: Couples who decline screening, at enrolment (Day 0); optional. Couples who accept screening, at enrolment (Day 0); compulsory

    Questions with randomised monetary values to assess maximum amount participants would be willing to pay, and whether the test should be government, privately or Medicare funded.

  14. Participant Experience - Health Literacy

    Time frame: At provision of samples for screening, anticipated to be within ten days of enrolment (Days 2-10); optional

    Questions to assess health literacy level

  15. Participant Experience - Evaluation of Educational and Decision-Aid Materials

    Time frame: At provision of samples for screening, anticipated to be within ten days of enrolment (Days 2-10); optional

    Questions to evaluate resources developed for participating couples e.g. decision aid, website, brochure

  16. Participant Experience - Decisional Conflict

    Time frame: At provision of samples for screening, anticipated to be within ten days of enrolment (Days 2-10); optional

    16-item scale measuring personal perception of uncertainty, factors contributing to uncertainty, and effective decision making. Includes five subscores: uncertainty, informed, values clarity, support, effective decision making (O'Conner 1993 (updated 2010)). Total scores range from 0 [no decisional conflict] to 100 [very high decisional conflict].

  17. Participant Experience - Deliberation

    Time frame: At provision of samples for screening, anticipated to be within ten days of enrolment (Days 2-10); optional

    6-item scale measuring decision deliberation. Dichotomous scale: responses below the midpoint (11 or under) classified as not deliberated and those at or above the midpoint as deliberated (Van den Berg, Timmermans, Ten et al 2006)

  18. Participant Experience - Decision-Making Approach

    Time frame: At provision of samples for screening, anticipated to be within ten days of enrolment (Days 2-10); optional

    Survey evaluating decision-making approach i.e. whether it was an individual or shared decision and who was involved in the decision-making process, e.g. couples, family, health-professional

  19. Participant Experience - Genomics Outcome Scale (GOS-6)

    Time frame: Increased-risk couples, before and after genetic counselling session (~Weeks 5-6 since enrolment)

    6-item scale measuring empowerment as an outcome of clinical genetics services. Total scores range from a minimum of 6 to a maximum of 30. Higher scores indicate higher levels of empowerment (Grant et al. 2018)

  20. Participant Experience - Decisional Regret - post-result

    Time frame: Low-risk and increased-risk couples; post-result (~Weeks 17-18 since enrolment); optional

    A 5-item scale measuring distress and remorse after a health care decision. Scores range from 0 [no regret] to 100 [high regret]. Subset of low-risk couples to be contacted for interview to explore experience of having testing and receiving a low-risk result.

  21. Participant Experience - Decisional Regret - long-term follow-up

    Time frame: Low-risk couples; long-term follow-up (~13 months since enrolment); optional. Increased-risk couples; long-term follow-up (~19 months since enrolment); optional

    A 5-item scale measuring distress and remorse after a health care decision. Scores range from 0 [no regret] to 100 [high regret]. Subset of low-risk couples to be contacted for interview to explore experience of having testing and receiving a low-risk result.

  22. Participant Experience - Qualitative Interviews

    Time frame: Low-risk couples; long-term follow-up (~13 months since enrolment); optional. Increased-risk couples; long-term follow-up (~19 months since enrolment); optional

    Subset of low-risk couples to be contacted for interview to explore longer-term experience of having testing and receiving a low-risk result. Subset of increased-risk couples to be contacted for interview to explore the experience of receiving a increased-risk result, the use of this information in reproductive decision-making, and the communication of genetic information within families.

Other outcomes

  1. Ethical Issues - Assessment of ethical aspects of publicly funded preconception screening

    Time frame: Throughout study; 3 years

    A series of scholarly outputs (e.g. journal articles) critically considering ethical issues in publicly funded preconception screening programs. The issues being identified include (but are not limited to) reproductive autonomy, public health ethics frameworks, eugenics, secondary findings. Additional ethical issues will be considered as they arise in the trial. The method to be used is applied ethics, which is non-empirical.

  2. Implementation Outcomes - Barriers & Enablers to Implementation

    Time frame: Study investigators; at committee meetings for the duration of the study (3 years); Jan 2019 - Dec 2022

    Barriers and enablers to implementation will be identified and recorded at study committee meetings via responses to the following questions: What has changed over the last month or so? What has gone well/not so well? Has anything surprised you?

  3. Implementation Outcomes - Anticipated vs Actual Outcomes

    Time frame: Study investigators; 1 month before the study begins recruitment

    To assess whether planned and anticipated outcomes are realised, study investigators will be asked to complete a time-capsule survey predicting the outcomes of the study. Following the completion of the study, the responses will be matched to the final outcomes.

  4. Implementation Outcomes - Patient Safety Behaviour Questionnaire

    Time frame: HCPs; at HCP conferences or professional meetings; for the duration of the study (3 years).

    Questionnaire assessing what HCPs in the wider community think about carrier screening, and what the barriers/enablers are to offering carrier screening to patients in usual care.

  5. Implementation Outcomes - Uptake by HCPs

    Time frame: HCPs; at invitation to become a recruiting HCP; for the duration of the study (3 years)

    Survey of HCPs invited to recruit to the study, including those who agree to recruit couples and those who decline to recruit couples. The survey will explore potential barriers to RGCS, factors that might influence confidence/ability to refer appropriate couples for RGCS and readiness to change. HCPs can opt-in to be contacted for interview to provide further information about implementation.

  6. Implementation Outcomes - Factors influencing Recruitment by HCPs - post-education

    Time frame: Recruiting HCPs; 3 months after education

    Survey of HCPs who agree to recruit to the study, measuring factors influencing recruitment such as knowledge, ability and confidence.

  7. Implementation Outcomes - Factors influencing Recruitment by HCPs - post-recruitment

    Time frame: Recruiting HCPs; 6 weeks after recruitment of first participant

    Survey of HCPs who have recruited to the study, measuring factors influencing recruitment. Opt-in to be contacted for interview to further explore the experience of offering RGCS to patients and any barriers/enablers of implementation.

  8. Implementation Outcomes - HCP Experience - post-implementation

    Time frame: Recruiting HCPs; 3 months after end of recruitment

    Survey of HCPs who have recruited to the study, examining their experience of offering reproductive genetic carrier screening.

  9. Health Economic Impact - Costs per increased-risk couple identified

    Time frame: 3 months after enrolment

    Cost in Australian dollars of identifying one increased-risk couple

  10. Health Economic Impact - Costs per affected pregnancy identified

    Time frame: 6 months after enrolment

    Cost in Australian dollars of identifying one affected pregnancy

  11. Health Economic Impact - Costs per affected birth averted

    Time frame: Throughout study; 3 years

    Average cost in Australian dollars of taking reproductive measures to avoid having an affected live birth (e.g. pre-implantation genetic diagnosis, prenatal diagnosis, termination etc.)

  12. Health Economic Impact - Costs of the carrier screening program

    Time frame: Throughout study; 3 years

    Total costs of the carrier screening program

Sponsors and collaborators

Lead sponsor

Murdoch Childrens Research Institute

Other

Collaborators

  • Australian Government Department of Health and Ageing
  • Griffith University
  • Harry Perkins Institute of Medical Research
  • King Edward Memorial Hospital
  • Macquarie University, Australia
  • NSW Health Pathology
  • PathWest Laboratory Medicine WA
  • Royal Brisbane and Women's Hospital
  • Royal Hobart Hospital
  • Sydney Children's Hospitals Network
  • The University of New South Wales
  • The University of Western Australia
  • University of Sydney
  • Victorian Clinical Genetics Services
  • Women's and Children's Hospital, Australia

Registry information

Important dates

Study start
2019
Primary completion
2022
Study completion
2024
First posted
Nov 8, 2019
Registry last updated
Jul 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.